Summary

PEG 3350 Market Research Report Information by Product Type (Powder, Bowel Preparation Kit) by Age (Pediatric, Adult, and Geriatric) by Application (Constipation, Medical Tests, [Colonoscopy and Barium Enema X-Ray Examination], and Surgery) by Distribution Channel (Online Pharmacy, Offline Pharmacy), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview
The PEG 3350 market was valued at USD 1.92 billion in 2023. The PEG 3350 Market industry is expected to increase from USD 2.08 billion in 2024 to USD 3.71 billion by 2032, with a compound yearly growth rate (CAGR) of 6.63% over the forecast period (2024-2032). The increased prevalence of colon cancer in India and other emerging countries, as well as an increase in strategic activities, are driving market expansion.
The incidence of colon cancer is rising worldwide. For example, according to an article published in Lancet Regional Health Southeast Asia, colon cancer is the seventh most frequent cancer in India, with 65,358 new cases expected in 2021. The global incidence of colon cancer has been increasing, and it is now 19.5 per 100,000 people, with 15.2 per 100,000 in India. Similarly, changing behaviors, such as consuming a calorie-rich and low-fiber diet, eating too much red meat and processed foods, and being physically inactive. In addition, the age-sex-adjusted rates of colon cancer in India have risen by 20.6%, with a high increase among persons under the age of 50.
As a result, the increased incidence of colon cancer is expected to drive up demand for PEG 3350. This cumulative prevalence of colon cancer, together with changing lifestyle choices such as rising alcohol and tobacco usage, rising smoking rates, and bad dietary habits among the population, is predicted to boost the PEG 3350 markets over the forecast period.

Market Segment insights
The PEG 3350 market segmentation is based on powder and bowel prep kits.
The market is divided into three segments based on age: pediatric, adult, and geriatric.
The PEG 3350 Market is segmented by application, which includes constipation and medical testing. and surgery.
The market is segmented based on distribution channels, which include online and offline pharmacies.

Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American PEG 3350 market had the biggest market share in 2022. This is attributable to the increased occurrence of colorectal cancer, as well as other ailments like diabetes, cancer, and neurological disorders in North America.
The PEG 3350 market in Europe is the second-largest due to the increased frequency of colorectal cancer and the region's increasing acceptance of sedentary lifestyles. Furthermore, the Germany PEG 3350 Market was ascribed with the greatest market share and is predicted to be the fastest-growing market in the European area.
The Asia-Pacific PEG 3350 market is predicted to develop significantly between 2024 and 2032. This is attributed to an increasing senior population, the adoption of sedentary lifestyles and physical inactivity, and the increased prevalence of colorectal cancer in Asia-Pacific countries. Furthermore, China PEG 3350 Market is estimated to hold the greatest market share, followed by India. The PEG 3350 market is predicted to be the fastest-growing in the Asia-Pacific region.
The rest of the world is divided into three regions: the Middle East, Africa, and Latin America. The PEG 3350 Market in the aforementioned regions is expected to expand due to a lack of understanding regarding the proper diet. Furthermore, according to the report, colorectal cancer is on the rise in the Middle East in both young and older adults, and it causes frequent constipation in children, supporting the region's market expansion.

Major Players

Teva Pharmaceutical Industries Ltd (Israel), LGM Pharma (US), McKesson Corporation (US), Sisco Research Laboratories Pvt. Ltd. (India), BASF SE (Germany), Merck KGaA (US), Bayer AG (Germany), Lupin Pharmaceuticals, Inc (India), Breckenridge Pharmaceutical, Inc. (US), and Pendopharm (Canada) are among the key players in the PEG 3350 Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING PREVALENCE OF COLON CANCER IN INDIA AND OTHER DEVELOPING NATIONS
4.2.2 RISING NUMBER OF STRATEGIC INITIATIVES
4.2.3 INCREASING SEDENTARY LIFESTYLE AND PHYSICAL INACTIVITY
4.3 RESTRAINTS
4.3.1 SIDE EFFECTS ASSOCIATED WITH PEG 3500
4.3.2 INCREASING PREFERENCE FOR ORGANIC ALTERNATIVES
4.4 OPPORTUNITIES
4.4.1 ENTERING DEVELOPING MARKETS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION
5.1.4 MARKETING & SALES
5.1.5 POST-SALES REVIEW/MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL PEG 3350 MARKET
5.3.1 IMPACT ON DEMAND
5.3.2 IMPACT ON SUPPLY CHAIN
5.3.3 IMPACT ON MARKET PLAYERS
6 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 POWDER
6.3 BOWEL PREPARATION KIT
7 GLOBAL PEG 3350 MARKET, BY AGE
7.1 OVERVIEW
7.2 PEDIATRIC
7.3 ADULT
7.4 GERIATRIC
8 GLOBAL PEG 3350 MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 CONSTIPATION
8.3 MEDICAL TESTS
8.3.1 COLONOSCOPY
8.3.2 BARIUM ENEMA X-RAY EXAMINATION
8.4 SURGERY
9 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 ONLINE PHARMACY
9.3 OFFLINE PHARMACY
10 GLOBAL PEG 3350 MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL PEG 3350 MARKET
11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL PEG 3350 MARKET
11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.5.1 PRODUCT LAUNCH/PRODUCT APPROVAL
12 COMPANY PROFILES
12.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL ANALYSIS
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 KEY STRATEGIES
12.2 LGM PHARMA
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIES
12.3 MCKESSON CORPORATION
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 SISCO RESEARCH LABORATORIES PVT. LTD.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 BASF SE
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 MERCK KGAA
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 BAYER AG
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 LUPIN PHARMACEUTICALS, INC.
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 BRECKENRIDGE PHARMACEUTICAL, INC.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 PENDOPHARM
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS